Deferasirox in the management of iron‐overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON‐M study).

At present, very few data are available on the role of iron chelation therapy (ICT) with deferasirox (DFX) in MF (Elli I et al i , [3]; Latagliata I et al i , [5]). Patients received DFX after a median MF duration of 26-8 months [interquartile range (IQR) 2-6-208-7] with a TD latency of 12-5 months (IQR 1-2-146-1). Our preliminary data open new insights regarding the benefit of DFX in MF patients with TD anaemia. [Extracted from the article]